ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05475821
- Locations
- 🇺🇸
Acpru /Id# 247995, Grayslake, Illinois, United States
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
- Conditions
- High Grade Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT05456685
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States
A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth
- Conditions
- Perioral Lines
- Interventions
- Device: JUVÉDERM® VOLITE™Other: Control
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 198
- Registration Number
- NCT05454033
- Locations
- 🇨🇳
The Third Affiliated Hospital, Sun Yat-Sen University /ID# 231398, Guangzhou, Guangdong, China
🇨🇳China-Japan Friendship Hospital /ID# 252139, Beijing, Beijing, China
🇨🇳Plastic Surgery Hospital(Institute), Cams, Pumc /ID# 231394, Beijing, Beijing, China
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT05451316
- Locations
- 🇯🇵
Tohoku Medical and Pharmaceuti /ID# 252486, Sendai-shi, Miyagi, Japan
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer
- Conditions
- Ovarian CancerPeritoneal CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 418
- Registration Number
- NCT05445778
- Locations
- 🇹🇷
Baskent University Hospital, Adana, Turkey
🇺🇸USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Honor Health Cancer Care, Biltmore, 2222 E. Highland Ave, #400, Phoenix, Arizona, United States
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
- Conditions
- Myelofibrosis
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 998
- Registration Number
- NCT05444972
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires /ID# 244373, Ciudad Autonoma Buenos Aires, Ciuadad Autonoma De Buenos Aires, Argentina
🇦🇷Fundaleu /Id# 244371, Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
🇮🇹Azienda Ospedaliera di Perugia /ID# 245415, Perugia, Umbria, Italy
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: CVL-231 30 mg
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 850
- Registration Number
- NCT05443724
- Locations
- 🇺🇸
Phoenix, Arizona, Phoenix, Arizona, United States
🇺🇸Little Rock, Arkansas, Little Rock, Arkansas, United States
🇺🇸Culver City, California, Culver City, California, United States
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 161
- Registration Number
- NCT05439616
- Locations
- 🇺🇸
Cincinnati Children's Hospital /ID# 243968, Cincinnati, Ohio, United States
🇺🇸Core Clinical Research /ID# 243084, Everett, Washington, United States
🇺🇸Family Psychiatry of The Woodlands /ID# 242867, The Woodlands, Texas, United States
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 270
- Registration Number
- NCT05424562
- Locations
- 🇨🇦
BC Cancer - Victoria /ID# 257339, Victoria, British Columbia, Canada
🇨🇦BC Cancer - Surrey /ID# 257515, Surrey, British Columbia, Canada
🇨🇦Vancouver General Hospital /ID# 245438, Vancouver, British Columbia, Canada
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
- Conditions
- Non-infectious Intermediate Posterior- or Pan-uveitis
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 87
- Registration Number
- NCT05414201
- Locations
- 🇨🇳
Peking University First Hospital /ID# 243055, Beijing, Beijing, China
🇨🇳Tianjin Medical University Eye Hospital /ID# 243056, Tianjin, China
🇨🇳The second affiliated hospital of Zhejiang University school of medicine /ID# 247251, Hangzhou, Zhejiang, China